New Syntrix Publication: Pharmacodynamic Properties of Methotrexate and Aminotrexate During Weekly Therapy
Congratulations to Syntrix scientists and collaborators at the University of Medicine and Dentistry of New Jersey for their published paper in Cancer Chemotherapy and Pharmacology.
Abstract excerpts: Aminopterin (AMT) has several advantages over the related antifolate methotrexate (MTX), including greater potency, complete oral bioavailability, and greater accumulation by leukemic blasts in vitro. We compared the pharmacodynamic properties of equipotent doses of AMT and MTX in mice and children with acute lymphoblastic leukemia. AMT and MTX had equivalent penetration into the bone marrow in mice and patients. However, MTX concentrations in the brain or cerebrospinal fluid after oral dosage were significantly greater than AMT. Selective exclusion of AMT from the CNS compartment suggests AMT may a better CNS toxicity profile than MTX.
Link to paper in Pubmed.
Read about L/D-aminopterin in our pipeline.